• A joint institute of Tampere University of Technology and University of Tampere.
  • Multidisciplinary research and education: from genetics to engineering.
  • Pioneering discoveries and innovations in life sciences.

Human Pluripotent Stem Cells Offer a New Approach for Corneal Reconstruction

Limbal stem cell deficiency, caused by lack of functional limbal epithelial stem cells (LESCs), is a debilitating eye disease characterized by loss of corneal clarity and visual impairment. LESCs derived from human pluripotent stem cells offer a novel approach for corneal reconstruction, yet careful evaluation of these cells is important before proceeding towards clinical applications. In this study, mass spectrometry-based proteomics technique was used to compare these cells to their native counterparts. Read the article published in Scientific Reports by BioMediTech researchers in collaboration with School of Medicine (University of Tampere) and University of Szeged, Hungary.

Cell Mechanics Are More Complex than Previously Thought

Cell mechanics are considerably more complex than previously thought and may affect cell structures at various levels. This finding is based on a collaborative research project conducted by an international research team from ETH Zurich and BioMediTech, involving Teemu Ihalainen, a postdoctoral researcher at the Academy of Finland.  The project was characterised by an interdisciplinary approach which combined cellular and molecular biology with research on biomaterials. The findings of the team were published in the Nature Materials online publication.

Global Regenerative Medicine Market Shows Strong Growth

The market for human spare parts is growing rapidly. While the market is still relatively small worldwide, all the indicators are pointing up. BioMediTech’s seminar brought together scientists and companies to discuss the latest developments in the field.

”From a consumer perspective, examples of the most intriguing innovations being adopted by the healthcare sector are a novel method for determining whether a particular cardiac medication will be effective in an individual patient and new stem cell-based treatments for incontinence. In the field of eye research, we’re currently testing new methods for retinal repair through cell transplantation, Professors Minna Kellomäki and Heli Skottman from BioMediTech say.

Read more from UTA blog

Adult and Stem Cell-derived Cardiac Cells Respond Similarly to Selective Current Blockers

Cardiac safety has always been a critical issue and expensive part in the drug development process. The integration of two new technologies, i.e. in vitro experiments on cardiac cells derived from human stem cells and in silico – computational – experiments by means of human ventricular models, holds the promise to dramatically change the cardiotoxicity assessment of new drugs.

BioMediTech researchers found out that adult and stem cell-derived cardiac cells respond similarly to selective current blockers, but sometimes with different sensitivities. E.g. for the L-type calcium current or for the inward rectifier potassium current. This result is good news for the use of stem cell derived-cardiac cells as such over-sensitivity can be used to ease the identification of desired or adverse drug effects. Moreover, this is a clear example of how predictions, obtained through in silico models, can actively support the pharmacological research. Read the article published in British Journal of Pharmacology.

BioMediTech Annual Report 2014

BioMediTech Annual Report 2014 has been published. Read the annual report here.






6.10.2015 at 18.00 Café Scientific on “Kaupunki-ilman pienhiukkaset”  (“small parts of the city air”), speaker Professor Jyrki Mäkelä, TUT @Monitoimitalo 13, Satakunnankatu 13, Stage-hall. Speech in Finnish.

16.10.2015 at 9.30 BioMeditech Seminar “Molecules of Life” @Finn-Medi 5, Main Auditorium. The seminar continues until 12.30, and it is followed by Professor Markku Kulomaa’s farewell lecture, which starts at 2 o’clock. The seminar is free of charge and open for all, but please register by 14.10.2015 www.biomeditech.fi/kulomaa_farewell_lecture/

5.-6.11.2015 1st Annual Finnish Symposium on Brain Tumors. Finnish brain tumor research association (FiBTRA) will organise the 1st Annual Finnish Symposium on Brain Tumors in 5.-6. November 2015 in Tampere. The 1st Annual Finnish Symposium on Brain Tumors will welcome all scientists and clinicians who work with brain tumors or are interested in brain tumor research. The registration and abstract submission is now open in  http://fibtra.org/ Deadline for abstract submission is Sunday, October 18, 2015,. 23:00 p.m. and online registration closes on Sunday, October 25, 2015, 23:00 p.m.


Biokatu 10
33520 Tampere
email info@biomeditech.fi

University of Tampere
BioMediTech / University of Tampere
Tampere University of Technology
BioMediTech / Tampere University of Technology

We are present in LinkedIn

© BioMediTech 2011-2015